Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV001075160 | SCV001240772 | pathogenic | Retinal dystrophy | 2018-10-09 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001093124 | SCV001249954 | pathogenic | not provided | 2017-09-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001093124 | SCV001578007 | pathogenic | not provided | 2024-12-17 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 543 of the TTLL5 protein (p.Glu543Lys). This variant is present in population databases (rs199882533, gnomAD 0.06%). This missense change has been observed in individuals with retinal dystrophy (PMID: 24791901, 28173158). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 139517). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TTLL5 protein function. Experimental studies have shown that this missense change affects TTLL5 function (PMID: 27162334). For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV001075160 | SCV005073123 | pathogenic | Retinal dystrophy | 2022-01-01 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000128418 | SCV000172095 | pathogenic | Cone-rod dystrophy 19 | 2014-05-01 | no assertion criteria provided | literature only |